THYROLAR-5 Drug Patent Profile
✉ Email this page to a colleague
When do Thyrolar-5 patents expire, and when can generic versions of Thyrolar-5 launch?
Thyrolar-5 is a drug marketed by Allergan and is included in one NDA.
The generic ingredient in THYROLAR-5 is liotrix (t4;t3). Additional details are available on the liotrix (t4;t3) profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for THYROLAR-5?
- What are the global sales for THYROLAR-5?
- What is Average Wholesale Price for THYROLAR-5?
Summary for THYROLAR-5
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 95 |
| Patent Applications: | 4,206 |
| DailyMed Link: | THYROLAR-5 at DailyMed |
US Patents and Regulatory Information for THYROLAR-5
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Allergan | THYROLAR-5 | liotrix (t4;t3) | TABLET;ORAL | 016807-006 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
